[Application of angiotensin II receptor blocker in prostate cancer].
Since a low prevalence of cancer in hypertensive patients receiving angiotensin converting enzyme inhibitors was reported, a biological action of angiotensin II (Ang-II) on the development or progression of cancer has been drawn attention. Recently, a widespread use of AT1 receptor blockers (ARBs) has contributed more attractive information on the involvement of Ang-II in cancer. Interestingly, there is increasing evidence that the renin -angiotensin system is implicated in the development of various cancers. From basic and clinical data, we believe that ARB has a novel ability to decelerate prostate specific antigen elevation especially in hormone refractory cancer and suppress the incidence of prostate cancer, which implies that ARB may have a chemopreventive activity for prostate cancer.
Department of Urology, Yokohama City University Graduate School of Medicine.
Hiroji
H
Uemura
Yoshinobu
Y
Kubota
D057911:Angiotensin Receptor Antagonists; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D014407:Tumor Cells, Cultured / Q000187:drug effects
D057911:Angiotensin Receptor Antagonists